Results 221 to 230 of about 19,833 (262)

Wildagliptyna – wyjątkowy inhibitor DPP-4

Medycyna Faktów, 2022
Wildagliptyna jest jedynym lekiem z grupy inhibitorów DPP-4, który stosuje się 2 razy dziennie. Chociaż nie przeprowadzono badania poświęconego bezpieczeństwu sercowo-naczyniowemu stosowania tego leku, to licznie opublikowane metaanalizy oraz badania obserwacyjne jednoznacznie potwierdziły bezpieczeństwo wildagliptyny w tym zakresie.
openaire   +1 more source

DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control

Archives of Pharmacal Research, 2016
Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are an emerging class of antidiabetic drugs that constitutes approximately fifty percent of the market share of the oral hypoglycemic drugs. Its mechanism of action for lowering blood glucose is essentially via inhibition of the rapid degradation of incretin hormones, such as glucagon-like peptide ...
openaire   +2 more sources

Inappropriate Use of DPP-4 Inhibitors

2014
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents for the treatment of type 2 diabetes. They have shown reduction of blood glucose, but potential impact on cardiovascular outcomes and long-term safety remain inconclusive. For that reasons DPP-4[for full text, please go to the a.m. URL]
Reichel, A, Blank, S, Tamminga, M, Schoch, GG, Steimle, T   +4 more
openaire   +1 more source

How safe are DPP‐4 inhibitors?

Practical Diabetes, 2013
AbstractAbstract.
Laura McCreight, Miles Fisher
openaire   +1 more source

[DPP-4 inhibitors in nephropatics].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
The use of glucose-lowering drugs in advanced stage diabetic nephropathic patients should be done very carefully. Some drugs are contraindicated or not recommended. The same insulin needs a dose reduction to avoid dangerous hypoglycemia. For some years the use of inhibitors of the DDP-4 has been approved in T2DM patients with CKD III and IV stage ...
Annamaria, Bruzzese, Maria, Pasquale, Carmela, Aloisi, Giuseppe, Costantino, Michele, Buemi   +4 more
openaire   +1 more source

[Once-weekly DPP-4 inhibitor].

Nihon rinsho. Japanese journal of clinical medicine, 2016
Trelagliptin is the first once-weekly dipeptidyl peptidase-4(DPP-4) inhibitor in the world. Trelagliptin inhibits DPP-4 activity with lower drug concentration compared with other once- (or twice-) daily DPP-4 inhibitors in in vitro study. More than 70 % of DPP-4 activity is inhibited even 1 week after administration of trelagliptin administration in ...
Norio, Harada, Nobuya, Inagaki
openaire   +1 more source

DPP-4 Inhibitors

2017
T. Biftu, R. SinhaRoy
openaire   +1 more source

DPP-IV Inhibitor–Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema

Journal of Investigative Medicine High Impact Case Reports, 2021
Chidinma Ejikeme
exaly  

Synthesis of a DPP-4 Inhibitor

Synfacts, 2020
openaire   +1 more source

Review on Chemistry, Analysis and Pharmacology of Teneligliptin: A Novel DPP-4 Inhibitor

Mini-Reviews in Medicinal Chemistry, 2020
Ketan Hatware, Patil Kiran D, Sanjay Sharma   +2 more
exaly